BOSTER
antibody and ELISA experts

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-LRP1/Lrp 1 Cluster Ii Rabbit Monoclonal Antibody

Catalog Number: M00829

Overview

Product Name	Anti-LRP1/Lrp 1 Cluster Ii Rabbit Monoclonal Antibody
Reactive Species	Human, Mouse, Rat
Description	Boster Bio Anti-LRP1/Lrp 1 Cluster Ii Rabbit Monoclonal Antibody catalog # M00829. Tested in WB, IHC, ICC/IF, IP, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.
Application	Flow Cytometry, IP, IF, IHC, ICC, WB
Clonality	Monoclonal BDC-12
Formulation	Rabbit IgG in stabilizing components, phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. *This antibody is supplied in a stabilized formulation. Compatibility with conjugation reactions depends on the chemistry of the conjugation method used. For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.
Storage Instructions	Store at -20°C for one year. For short term storage and frequent use, store at 4°C for up to one month. Avoid repeated freeze-thaw cycles.
Host	Rabbit
Uniprot ID	Q07954

Technical Details

Immunogen	A synthesized peptide derived from human LRP1
Isotype	Rabbit IgG
Form	Liquid
Concentration	0.5mg/ml
Purification	Affinity-chromatography
Suggested Dilutions	WB 1:1000-5000 IHC 1:50-200 ICC/IF 1:50-200 IP 1:20 FC 1:20

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Anti-LRP1/Lrp 1 Cluster Ii Rabbit Monoclonal Antibody (M00829) Images



Western blot analysis of LRP1/Lrp 1 Cluster Ii using anti-LRP1/Lrp 1 Cluster Ii antibody (M00829). Electrophoresis was performed on a 10% SDS-PAGE gel at 80V (Stacking gel) / 120V (Resolving gel) for 2 hours. The sample well of each lane was loaded with 30 ug of sample under reducing conditions. Lane 1: human U87 whole cell lysates, Lane 2: human HepG2 whole cell lysates, Lane 3: human U20S whole cell lysates, Lane 4: human Hela whole cell lysates, Lane 5: rat brain tissue lysates, Lane 6: rat heart muscle tissue lysates, Lane 7: mouse brain tissue lysates, Lane 8: mouse heart tissue lysates. After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-LRP1/Lrp 1 Cluster Ii antigen affinity purified monoclonal antibody (M00829) at 1:500 overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:1000 for 1.5 hour at RT. The signal is developed using an ECL Plus Western Blotting Substrate (Catalog # AR1196-200) with Tanon 5200 system. A specific band was detected for LRP1/Lrp 1 Cluster Ii at approximately 85 kDa. The expected band size for LRP1/Lrp 1 Cluster Ii is at 85 kDa.



All lanes use the Antibody at 1:3W dilution for 1 hour at room temperature.



Membrane-receptor LRP1 is responsible for the stimulatory effect of CD44s-tPA on lamellipodia formation (A) The distribution patterns of cortactin (red) and F-actin (green) demonstrated by immunofluorescence staining in control and LRP1 inhibitor (RAP, 200 nM), Annexin A2 inhibitor (LCKLSL, 2.5 μM), and EGFR inhibitor (AG1478, 10 μM) pretreated CD44s-overexpressing MCF7 cells. The elongated lamellipodia are highlighted by the arrows. The proportion of cells with lamellipodia in control and RAP, LCKLSL, and AG1478 pretreated groups were calculated from triplicate independent experiments, means ± SD from triplicate experiments were plotted. (B) Representative images and quantitative analysis of migration assay showing the wound closure rate of control and RAP pretreated MCF7 CD44s cells. The means ± SD of wound closure rates from triplicate experiments were plotted. (C) Analysis of LRP1 expression in control and LRP1 knockdown MCF7CD44s cells. (D)

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com

Representative images and quantitative analysis of migration assay showing the wound closure rate of control and LRP1 knockdown MCF7 CD44s cells. The means ± SD of wound closure rates from triplicate experiments were plotted. (E) Representative images and quantitative analysis of migration assay showing the wound closure rate of control and LRP1 knockdown MCF7 CD44s cells. The means ± SD of wound closure rates from triplicate experiments were plotted. n. s. Indicates no significant, ** p < 0.01, *** p < 0.001.Index in PubMed under a CC BY license. PMID: 37842093



tPA/LRP1 axis enhances the lamellipodia formation through NFkappaB signaling pathway. (A) Gene set enrichment analysis (GSEA) enrichment plots of the hallmark of NFkappaB gene sets in MCF7 CD44s compared with MCF7 vector groups. (B) Analysis of phosphorylation of p65, total p65 protein levels in MCF7 vector , MCF7 CD44s , and LRP1 knockdown MCF7 CD44s cells by western blot. (C) Analysis of phosphorylation of p65, total p65 protein levels in control and RAP pretreated MCF7 CD44s cells by western blot. (D) Analysis of phosphorylation of p65, total p65 protein levels in control and NFkappaB pathway inhibitor (BAY 11-7082, 10 μM) pretreated MCF7 CD44s cells by western blot. (E) The distribution patterns of cortactin (red) and F-actin (green) demonstrated by immunofluorescence staining in control and BAY 11-7082 pretreated CD44s-overexpressing MCF7 cells. The elongated lamellipodia are highlighted by the arrows. The proportion of cells with lamellipodia in control and BAY 11-7082 pretreated groups were calculated from triplicate independent experiments, means ± SD from triplicate experiments were plotted. (F) Representative images and quantitative analysis of migration assay showing the wound closure rate of control and BAY 11-7082 pretreated MCF7 CD44s cells. The means ± SD of wound closure rates from triplicate experiments were plotted. * p < 0.05.Index in PubMed under a CC BY license. PMID: 37842093



Western blot analysis of LRP1 expression in A549 cell lysate.

Immunohistochemical analysis of paraffin-embedded human liver carcinoma, using LRP1 Antibody.

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com





Immunohistochemical analysis of paraffin-embedded Human pituitary tumor, using the Antibody at 1:300 dilution.



Immunohistochemical analysis of paraffin-embedded Human prostate cancer, using the Antibody at 1:300 dilution.



Immunohistochemical analysis of paraffin-embedded Human breast cancer, using the Antibody at 1:300 dilution.



Immunofluorescent analysis using the Antibody at 1:50 dilution.

BOSTER BIOLOGICAL TECHNOLOGY
3942 B Valley Ave, Pleasanton, CA 94566
888-466-3604 | support@bosterbio.com | www.bosterbio.com



Flow cytometric analysis of LRP1 was done on Hela cells. The cells were fixed, permeabilized and stained with the primary antibody (1/50) (blue). After incubation of the primary antibody at room temperature for an hour, the cells were stained with a Alexa Fluor 488-conjugated Goat anti-Rabbit IgG Secondary antibody at 1/1000 dilution for 30 minutes.Unlabelled sample was used as a control (cells without incubation with primary antibody; red).

Anti-LRP1/Lrp 1 Cluster Ii Rabbit Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.